Dual-5α-Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man | Zendy

Jonathan Hazlehurst | Zendy; Andrei I. Oprescu | Zendy; Nikolaos Nikolaou | Zendy; Riccardo Di Guida | Zendy; Annabel Grinbergs | Zendy; Nigel P. Davies | Zendy; Robert Flintham | Zendy; Matthew J. Armstrong | Zendy; Angela E. Taylor | Zendy; Beverly Hughes | Zendy; Jinglei Yu | Zendy; Leanne Hodson | Zendy; Warwick B. Dunn | Zendy; Jeremy Tomlinson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Dual-5α-Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man

Author(s) -

Jonathan Hazlehurst,

Andrei I. Oprescu,

Nikolaos Nikolaou,

Riccardo Di Guida,

Annabel Grinbergs,

Nigel P. Davies,

Robert Flintham,

Matthew J. Armstrong,

Angela E. Taylor,

Beverly Hughes,

Jinglei Yu,

Leanne Hodson,

Warwick B. Dunn,

Jeremy Tomlinson

Publication year - 2015

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2015-2928

Subject(s) - endocrinology , medicine , dyslipidemia , chemistry , dihydrotestosterone , lipid metabolism , dutasteride , metabolome , finasteride , adipose tissue , pharmacology , biology , metabolite , androgen , diabetes mellitus , prostate , cancer , hormone

5α-Reductase 1 and 2 (SRD5A1, SRD5A2) inactivate cortisol to 5α-dihydrocortisol in addition to their role in the generation of DHT. Dutasteride (dual SRD5A1 and SRD5A2 inhibitor) and finasteride (selective SRD5A2 inhibitor) are commonly prescribed, but their potential metabolic effects have only recently been identified.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research